Skip to main content
. 2023 Nov 23;300(1):105492. doi: 10.1016/j.jbc.2023.105492

Figure 7.

Figure 7

Xenograft CRC and normal gastrointestinal tissue responses to MTDIA and AG-270 treatment.A and B, growth curves of WT HT-29 subcutaneous murine xenographs implanted bilaterally in the flanks of NOD/SID mice. Tumors measured via digital calipers (n = 12 tumors per condition). C, Western blotting of eight control and MTDIA (20 mg/kg) + AG-270 (200 mg/kg) tumors after 20 days treatment. Quantification normalized to GAPDH and performed in ImageJ. D, immunohistochemical analysis of SDMA and TUNEL apoptosis content in the HT-29 tumors from NOD/SCID mice and normal small and large intestinal Swiss Roll sections from C57/Bl6 mice after 20 and 15 days of treatment, respectively. Tumor samples were randomly imaged and quantification of SDMA intensity performed by selection of ten regions of interest (ROIs) approximately 150 μm2 in area per image with n = 16 imaged per treatment. Small and large intestinal sections were quantified by selecting epithelial cells in villi and crypts and weighting each ROI by total area. Scale bars represent 100 μm length. MTDIA, methylthio-DADMe-immucilin-A; SDMA, symmetric dimethylarginine.